VRTXVertex Pharmaceuticals
About Vertex Pharmaceuticals
Vertex Pharmaceuticals (NASDAQ:VRTX) focuses on developing and commercializing innovative therapies for treating cystic fibrosis (CF) and other severe diseases. The company is recognized for its leading portfolio of CF treatments which significantly improve the lives of those affected by this genetic disorder. Beyond CF, Vertex is expanding its research and development efforts into other serious diseases, aiming to apply its scientific expertise in creating transformative medicines. The overarching objective of Vertex is to deliver groundbreaking treatments that can profoundly impact the quality of life for patients with severe and life-threatening diseases. NASDAQ:VRTX is the sole exchange where Vertex Pharmaceuticals is traded, making it a noteworthy entity in the biotechnology sector for investors and industry stakeholders alike.
What is VRTX known for?
Snapshot
Public US
Ownership
1989
Year founded
5380
Employees
Boston, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Boston, US
Products and/or services of Vertex Pharmaceuticals
- Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor) - a leading medication for the treatment of cystic fibrosis, targeting the F508del mutation in people aged 6 years and older.
- Symdeko/Symkevi (tezacaftor/ivacaftor and ivacaftor) - a treatment for cystic fibrosis in patients aged 6 years and older with specific mutations in the CFTR gene.
- Orkambi (lumacaftor/ivacaftor) - designed for the treatment of cystic fibrosis in patients age 2 and older who have two copies of the F508del mutation in their CFTR gene.
- Kalydeco (ivacaftor) - a medication for the treatment of cystic fibrosis in patients aged 6 months and older with one of 38 ivacaftor-responsive mutations in the CFTR gene.
- Type 1 Diabetes therapy through the acquisition of ViaCyte, Inc. - focused on stem cell therapy that has the potential to provide a functional cure for type 1 diabetes.
- CRISPR/Cas9 gene-editing therapy in collaboration with CRISPR Therapeutics for the treatment of sickle cell disease and beta thalassemia, aimed at correcting mutations in the HBB gene coding for the beta-globin chain.
Vertex Pharmaceuticals executive team
- Dr. Jeffrey Marc Leiden M.D., Ph.D.Executive Chairman
- Dr. Reshma Kewalramani FASN, M.D.CEO, President & Director
- Mr. Charles F. Wagner Jr.Executive VP, COO & CFO
- Dr. David M. Altshuler M.D., Ph.D.Executive VP & Chief Scientific Officer
- Dr. Ourania Tatsis Ph.D.Executive VP and Chief Regulatory & Quality Officer
- Ms. Kristen C. Ambrose CPASenior VP & Chief Accounting Officer
- Ms. Susie Lisa C.F.A.Senior Vice President of Investor Relations
- Mr. Jonathan Biller J.D.Executive VP & Chief Legal Officer
- Ms. Nina DevlinSenior VP & Chief Communications Officer
- Ms. Stephanie FranklinSenior VP & Chief Human Resources Officer